Seasonal Allergic Rhinitis Treatment Market by Type of Treatment (Immunotherapy (Allergy Shots or Tablets), Antihistamines, Intranasal Corticosteroids, Decongestants, Leukotriene Modifiers), by Mode of Administration (Oral, Intranasal, Intramuscular or Subcutaneous, Sublingual), by Allergen Specificity (Pollen Allergies, Animal Allergies, Mold Allergies, Multiple Allergens), by Age Group (Pediatric, Adult), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa): Global Opportunity Analysis and Industry Forecast, 2023-2031

The Global Seasonal Allergic Rhinitis Treatment Market was valued at $XX million in 2022. It is projected to grow at a CAGR of XX% from 2023 to 2031 and reach more than $XX million by the end of 2031. 

Seasonal Allergic Rhinitis Treatment Market Analysis:

Seasonal allergic rhinitis is a condition caused by an allergic reaction to outdoor allergens such as pollen, dust, and pet hair. The most common symptoms include continuous sneezing, a runny nose, stuffy nose, itchy nose, itchy and watery eyes, sore and scratchy throat, coughing, frequent headaches, nasal congestion, postnasal drip, fatigue, itchy palate, and sleep-disordered breathing. The diagnosis is made based on the signs and symptoms observed during a physical examination. Other tests are further performed in order to confirm the diagnosis. The best treatment would be to identify and avoid allergens that cause the symptoms. If it is not entirely avoidable, steps should be taken to minimize the exposure. Medications such as nasal corticosteroids and antihistamines are also available to relieve inflammation and itching. Immunotherapy is used for severe allergies. Regular injection shots are given based on the blood test results so that the body can get immune to required allergens .

During the COVID-19 pandemic, a large population was struggling with chronic respiratory issues, such as respiratory allergies, including allergic rhinitis and sinusitis. An article published in February 2021 in the Journal of Allergy and Clinical Immunology reported the pandemic had a significant impact on allergy & immunology (A&I) services, leading to multiple unplanned pragmatic amendments in service delivery. There is an urgent need for prospective audits and strategic planning to achieve equitable, safe, and standardized health care in the medium and long term. Thus, the pandemic substantially impacted market growth in its preliminary phase. However, per the analysis, the treatment market for the same grew significantly with the growing burden of allergic diseases in the post-pandemic phase. For instance, per the study published by the Journal of Family Medicine and Primary Care in 2022, 24 patients were admitted with complaints of facial edema, nasal crusting, and orbital swelling. All cases were diagnosed as invasive fungal sinusitis. Specifically, mucormycosis, supported by clinical and radiological findings and potassium hydroxide (KOH) mounting. Moreover, the latest treatment strategies for allergies and research on new treatment approaches are expected to drive the market in the coming years.

The increasing burden of various types of allergies, the growing investment by manufacturers in developing novel allergic treatments, and the rising importance of self-medication are the major factors propelling the market's growth. Allergic conditions are one of the most common health issues affecting children in the United States. For instance, in 2021, the Asthma and Allergy Foundation of America (AAFA) reported that each year in the United States, anaphylaxis (a severe allergic reaction) to food results in 90,000 emergency room visits, and more than 50 million people in the United States experience various types of allergies each year. Asthma and Allergy Foundation of America (AAFA) 2021 data also reported that approximately 24 million people in the United States were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 8% (19.2 million) of adults and 7% (5.2 million) of children, and about 32 million people have food allergies. Thus, the growing prevalence of allergies is expected to increase demand for their treatment, thereby boosting the market's growth.

With the increase in allergic reactions, there are rising investments seen across the world for the development of novel treatments. For instance, in July 2022, Nestlé Health Science invested EUR 40 million (USD 41 million) to co-develop Enterome's preclinical IL-10 inducer and collaborate on discovering other food allergy candidates. Likewise, in February 2020, Aimmune Therapeutics also spent USD 10 million to in-license an experimental anti-allergenic biological drug from Xencor. Xencor granted Aimmune Therapeutics an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody AIMab7195 (originally XmAb7195). The drug was initially developed for the treatment of allergic asthma. It uses three distinct mechanisms of action to reduce blood serum IgE and suppress IgE-producing cells. All such factors are expected to propel the market during the forecast period.

However, the growing preference for low-cost biosimilars and lack of awareness regarding allergy immunotherapy can hamper the market's growth.

Seasonal Allergic Rhinitis Treatment Market Trends:

Biological treatments, including monoclonal antibodies, are emerging as a novel approach to SAR management. These therapies target specific molecules in the immune system responsible for allergic responses, providing effective relief for many patients. Advances in molecular diagnostics and genetics are enabling more personalized treatment approaches. Tailoring SAR treatments to an individual's specific allergens and immune responses can enhance efficacy and reduce side effects. The use of telehealth and digital health platforms for SAR management is on the rise. Patients can consult with healthcare providers remotely, receive prescriptions, and access educational resources, making it more convenient to manage their condition. Allergen immunotherapy, which includes subcutaneous and sublingual methods, is increasingly being used to desensitize patients to specific allergens. It offers a long-term solution for SAR by modifying the immune response.

Many SAR patients are exploring natural and alternative remedies, such as herbal supplements, acupuncture, and dietary changes, in addition to or as an alternative to conventional medication. Patient education is becoming a crucial aspect of SAR management. Informed patients are better equipped to manage their condition, recognize triggers, and make lifestyle adjustments to reduce symptoms. The development of apps and devices for tracking environmental allergen levels allows SAR sufferers to anticipate and mitigate symptoms. This trend aligns with the growing awareness of the impact of environmental factors on SAR. OTC medications for SAR continue to be popular, as they offer convenient and affordable relief for mild to moderate symptoms. These include antihistamines, decongestants, and intranasal corticosteroids.

Combining different types of medications, such as antihistamines and intranasal corticosteroids, can provide more comprehensive symptom relief and improve overall patient outcomes. Patients are increasingly adopting measures to reduce exposure to environmental allergens, such as using air purifiers, keeping windows closed during high pollen seasons, and maintaining clean indoor environments. Collaborative care between allergists, primary care physicians, and other healthcare providers is gaining importance to ensure comprehensive and effective SAR management. The SAR treatment market is expanding into emerging economies, where the prevalence of SAR is growing due to urbanization and changing environmental conditions. Evolving healthcare regulations, such as expedited approval processes for SAR medications and insurance coverage enhancements, are shaping the market landscape.

Additionally, per the study published in the International Archives of Allergy and Immunology in February 2021, subcutaneous allergen-specific immunotherapy (SCIT) is one of the main cornerstones in treating allergic rhinitis in pediatric patients. It demonstrated symptomatic relief and quality-of-life improvements but is not exempt from adverse reactions (ADRs). Thus, due to its safety established in pediatric patients, subcutaneous immunotherapy is expected to boost the segment over the forecast period.

The innovative launch of immunotherapy products and rising approval are major factors boosting the segments. In December 2021, the Omalizumab add-on offered efficacy benefits and improved allergen immunotherapy tolerability. Additionally, in July 2021, the United States FDA approved GSK's Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps.

Thus, all the factors mentioned above, such as the safety and efficacy of SCIT and product launches, are expected to boost segment growth over the forecast period.

Seasonal Allergic Rhinitis Treatment Market By Type of Treatment Segmentation:

Based on the Type of Treatment the market is Immunotherapy (Allergy Shots or Tablets), Antihistamines, Intranasal Corticosteroids, Decongestants, Leukotriene Modifiers. Immunotherapy (Allergy Shots or Tablets): This treatment involves exposing the patient to gradually increasing amounts of allergens, such as pollen or dust mites, to desensitize the immune system and reduce allergic reactions. Immunotherapy can be administered through allergy shots (subcutaneous immunotherapy) or tablets (sublingual immunotherapy). Antihistamines: Antihistamines are a common first-line treatment for SAR. They work by blocking the effects of histamine, a chemical that is released during an allergic reaction. Antihistamines are available in various forms, including oral tablets, liquids, and nasal sprays. Intranasal Corticosteroids: These are anti-inflammatory medications that are sprayed directly into the nasal passages. Intranasal corticosteroids help reduce nasal congestion, sneezing, and other SAR symptoms by decreasing inflammation in the nasal passages. Decongestants: Decongestants help relieve nasal congestion by narrowing blood vessels in the nasal passages. They are available in both oral and nasal spray forms. Decongestants are often used in combination with other SAR medications. Leukotriene Modifiers: Leukotriene modifiers are medications that target leukotrienes, which are chemicals in the body that contribute to allergic responses. They can be used to manage SAR symptoms, especially in individuals who have both SAR and asthma.

Seasonal Allergic Rhinitis Treatment Market By Mode of Administration Segmentation: 

Based on Mode of Administration the market is divided into Oral, Intranasal, Intramuscular or Subcutaneous, Sublingual. Oral: This segment includes SAR treatments that are taken by mouth, typically in the form of tablets, capsules, or liquid medications. Oral medications are convenient and often used for antihistamines and leukotriene modifiers. Intranasal: Intranasal medications are administered through the nasal passages and include intranasal corticosteroids and some antihistamine nasal sprays. These medications target symptoms directly in the nasal passages and sinuses. Intramuscular or Subcutaneous: This segment involves treatments that are administered via injection into the muscle (intramuscular) or under the skin (subcutaneous). Allergy shots (subcutaneous immunotherapy) are a common example in this category. They are a form of immunotherapy and are typically given by a healthcare provider at regular intervals. Sublingual: Sublingual treatments are administered by placing a tablet or liquid under the tongue, allowing for absorption through the mucous membranes. Sublingual immunotherapy (SLIT) tablets are an example of this mode of administration.

Seasonal Allergic Rhinitis Treatment Market By Allergen Specificity Segmentation:

Based on Allergen Specificity the market is divided into Pollen Allergies, Animal Allergies, Mold Allergies, Multiple Allergens. Pollen Allergies: Pollen allergies, also known as hay fever, are triggered by pollen from trees, grasses, and weeds. Treatments in this segment may specifically target pollen allergens, such as pollen extracts used in immunotherapy. Animal Allergies: Animal allergies are often caused by exposure to allergenic proteins found in pet dander, saliva, and urine. SAR triggered by animal allergens may require treatments that focus on reducing symptoms associated with pet exposure. Mold Allergies: Mold allergies are provoked by exposure to mold spores that are commonly found in damp or humid environments. SAR treatments specific to mold allergies may address the symptoms resulting from mold exposure. Multiple Allergens: Many individuals with SAR are allergic to multiple allergens. In such cases, treatments need to address the combination of allergens affecting the patient, making it more complex to manage their condition. This segment includes individuals who experience symptoms from a variety of allergens, such as pollen, animals, and molds.

Seasonal Allergic Rhinitis Treatment Market By  Age Group Segmentation: 

Based on Age group the market is divided into Pediatric, Adult. Pediatric: This segment includes children and adolescents who experience SAR. Pediatric SAR treatment may involve considerations related to age-appropriate dosages, forms of medication (e.g., liquid medications for young children), and the potential impact of SAR on a child's growth and development. Adult: The adult segment comprises individuals who have reached adulthood and experience SAR. SAR in adults may require different treatment strategies, considering factors such as comorbidities, medication interactions, and lifestyle considerations.

Seasonal Allergic Rhinitis Treatment Market Leaders

• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• AstraZeneca, GSK plc.
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG, Mylan N.V.
• Aytu BioPharma, Inc.
• Glenmark Pharmaceuticals Ltd
• Himalaya Wellness Company
• Regeneron Pharmaceuticals Inc.
• Allergy Therapeutics, Stallergenes Greer
• Bayer AG
• Dr. Reddy’s Laboratories Ltd
• ALK-Abelló A/S
• Revolo Biotherapeutics

These companies contribute significantly to the growth and innovation within the Seasonal Allergic Rhinitis Treatment Market, offering a wide range of solutions to meet the diverse needs of the biopharmaceutical, biotechnology, and research industries.

• In August 2022, Glenmark Pharmaceuticals’ arm has launched the only-approved fixed-dose combination therapy for seasonal allergic rhinitis in the United States market.
• In March 2022, Perrigo Company plc announced that it has received final approval from the US FDA for the over-the-counter use of Nasonex 24HR Allergy (mometasone furoate monohydrate 50mcg).